Eirini Thanopoulou

44 Lincoln's Inn Fields
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Journal: ESMO open
Published: January 16, 2026

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.

Journal: The New England journal of medicine
Published: June 02, 2025

Inavolisib Therapy in Advanced Breast Cancer. Reply.

Inavolisib Therapy in Advanced Breast Cancer. Reply.

Journal: The New England journal of medicine
Published: January 15, 2025

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

Journal: The New England journal of medicine
Published: October 30, 2024

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.

Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.

Journal: Cancers
Published: September 07, 2020

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 23, 2015

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital.

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital.

Journal: Clinical sarcoma research
Published: March 10, 2014

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.

Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors.

Journal: Clinical sarcoma research
Published: February 10, 2014

Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.

Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: February 09, 2014

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.

Journal: Breast cancer research and treatment
Published: January 25, 2014

Tumour heterogeneity and immune-modulation.

Tumour heterogeneity and immune-modulation.

Journal: Current opinion in pharmacology
Published: March 09, 2013

Hormonal therapy in gynecological sarcomas.

Hormonal therapy in gynecological sarcomas.

Journal: Expert review of anticancer therapy
Published: August 01, 2012
Showing 1-12 of 14

Last Updated: 09/26/2026